When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Strongyloides infection

Última revisão das evidências: 19 Sep 2026
Última atualização do tópico: 24 Jul 2026

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • history of soil exposure in an endemic area
  • infection with other parasites
Detalhes completos

Outros fatores diagnósticos

  • abdominal pain
  • altered bowel habit
  • weight loss
  • fever (hyperinfection)
  • signs of sepsis (hyperinfection)
  • chronic cough
  • wheezing
  • pruritus or dermatitis
  • larva currens
  • urticaria
  • cutaneous larva migrans
  • apparent drug reaction rash (hyperinfection)
  • other skin complaints
  • symptoms and signs of inflammatory bowel disease
  • signs of neurologic manifestations
Detalhes completos

Fatores de risco

  • soil exposure in endemic region or migrantion from an endemic region
  • corticosteroid use (risk of hyperinfection)
  • human T-cell lymphotropic virus type-1 (HTLV-1) infection (risk of hyperinfection)
  • international travelers
  • impaired immunity
  • solid-organ transplant recipient
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • stool ova and parasites (O&P) exam
  • CBC with differential
  • therapeutic trial of ivermectin (in specific situations)
Detalhes completos

Investigações a serem consideradas

  • sputum O&P exam
  • clinical sample (nonstool or sputum) O&P exam
  • strongyloides IgG serology
  • tissue biopsy
Detalhes completos

Novos exames

  • polymerase chain reaction (PCR)
  • strongyloides IgG4 urine

Algoritmo de tratamento

Inicial

immigrant from endemic area

AGUDA

able to tolerate oral therapy: not critically ill (nonpregnant)

unable to tolerate oral therapy or critically ill (nonpregnant)

pregnant

CONTÍNUA

poor clinical response or initial treatment not completed

Colaboradores

Autores

Louis M. Weiss , MD, MPH

Professor, Department of Pathology

Professor, Department of Medicine (Infectious Diseases)

Albert Einstein College of Medicine

Bronx, NY

Declarações

LMW has received grant funding from the National Institute of Health for research on Toxoplasma gondii and microsporidiosis. LMW receives training grants for infectious diseases at the Albert Einstein College of Medicine, and serves on the board of the Humane Society of Westchester.

Agradecimentos

Dr Louis M. Weiss would like to gratefully acknowledge Dr David R. Boulware, the previous contributor to this topic. DRB declares that he has no competing interests.

Revisores

Elizabeth Barnett, MD

Professor

Department of Pediatrics

Boston Medical Center

Boston University

Boston, MA

Declarações

EB declares that she is on a speaker's bureau for Merck.

Linda Nield, MD, FAAP

Professor of Pediatrics

West Virginia University School of Medicine

Morgantown, WV

Declarações

LN declares that she has no competing interests.

Geoff Gill, MA, MSc, MD, FRCP, DTMH

Professor of International Medicine and Honorary Consultant Physician

Liverpool School of Tropical Medicine

Liverpool

UK

Declarações

GG declares that he has no competing interests.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

World Gastroenterology Organisation. WGO practice guideline: management of strongyloidiasis. February 2018 [internet publication].Texto completo

Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016 Jan 18;(1):CD007745.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

O uso deste conteúdo está sujeito ao nosso aviso legal